David Snow, MD
Rheumatology · Delco, NCNPI 1639177082
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by AbbVie at 24.2% of the total. Reporting peaked in 2019 at $13,119 and has fallen 58.0% since, to $5,515 in 2025.
Across 1,117 payments — averaging $38.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Amgen$8K
- Gilead$5K
- Johnson & Johnson$4K
- Bristol Myers Squibb$3K
- UCB, Inc.$2K
- plus $10K from 30 others
Across 330 payments — averaging $10,099 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$2.4M
- Eli Lilly$439K
- AbbVie$277K
- Sun Pharmaceutical Industries Inc.$144K
- Gilead$46K
- Novartis$17K
- plus $11K from 2 others
What the payments were for
- Consulting fees$9,55522%
- Speaking & faculty fees$9,50022%
- Travel & lodging$5601%
- Food & beverage$23,19254%
- Education$1490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 166 | $10,378 |
| Amgen(2 entities) | 211 | $8,132 |
| Gilead | 8 | $5,199 |
| Johnson & Johnson | 102 | $4,457 |
| Bristol Myers Squibb | 4 | $2,935 |
| UCB, Inc. | 111 | $1,857 |
| Novartis | 89 | $1,803 |
| Pfizer | 117 | $1,668 |
| AstraZeneca(2 entities) | 44 | $1,033 |
| Radius Health, Inc. | 36 | $677 |
| Lilly USA, LLC | 42 | $658 |
| GSK | 28 | $559 |
| Aurinia Pharma U.S., Inc. | 20 | $464 |
| Organon | 19 | $409 |
| Fresenius Kabi USA, LLC | 17 | $405 |
| Mallinckrodt Hospital Products Inc. | 17 | $377 |
| E.r. Squibb & Sons, L.L.C. | 21 | $357 |
| Regeneron Healthcare Solutions, Inc. | 18 | $302 |
| Sanofi | 5 | $288 |
| Janssen Scientific Affairs, LLC | 2 | $186 |
| Boehringer Ingelheim | 9 | $172 |
| Sobi, Inc | 5 | $137 |
| ANI Pharmaceuticals, Inc. | 5 | $108 |
| Genentech USA, Inc. | 6 | $103 |
| Tersera Therapeutics LLC | 3 | $62 |
| Almatica Pharma LLC | 2 | $42 |
| Scilex Pharmaceuticals Inc. | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Fidia Pharma USA Inc. | 1 | $24 |
| Octapharma USA, Inc. | 1 | $23 |
| Biocryst US Sales Co., LLC | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Avion Pharmaceuticals | 1 | $15 |
| Invivyd Inc | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,956 in reported general payments places this provider in the 85th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 25 | $165,795 |
| Enbrel SureclickEtanercept | 17 | $144,536 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $108,152 |
| RinvoqUpadacitinib | 14 | $83,102 |
| Xeljanz XrTofacitinib Citrate | 14 | $78,028 |
| KevzaraSarilumab | 15 | $63,844 |
| Actemra ActpenTocilizumab | 17 | $62,993 |
| TymlosAbaloparatide | 20 | $51,901 |
| MethotrexateMethotrexate Sodium | 180 | $4,851 |
| Hydroxychloroquine Sulfate | 92 | $4,334 |
| Celecoxib | 102 | $2,838 |
| Febuxostat | 13 | $2,454 |
| Prednisone | 391 | $2,414 |
| Leflunomide | 44 | $1,877 |
| Diclofenac Sodium | 156 | $1,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $10,378 | $83,10214 claims |
| SanofiKevzara | $288 | $63,84415 claims |
| Radius Health, Inc.Tymlos | $677 | $51,90120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 210 rheumatology providers in North Carolina.
Other rheumatology in Delco
- Gordon LamCharlotte$2.7M
- Ralph SnydermanDurham$1.3M
- Wendy SimmonsWilmington$462K
- Andrew LasterCharlotte$421K
- Ana RossRaleigh$417K
- Gwenesta MeltonFayetteville$410K
- Joseph ShanahanDurham$407K
- Jill ZouzoulasCharlotte$377K
- Jill VargoAsheville$245K
- Robert HolmesPollocksville$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.